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Abstract
Background: There is considerable information on the methylation of the promoter regions of different genes
involved in gastric carcinogenesis. However, there is a lack of information on how this epigenetic process differs
in tumors originating at different sites in the stomach.
The aim of this study is to assess the methylation profiles of the MLH1, MGMT, and DAPK-1 genes in cancerous
tissues from different stomach sites.
Methods: Samples were acquired from 81 patients suffering stomach adenocarcinoma who underwent surgery
for gastric cancer in the Lithuanian University of Health Sciences Hospital Kaunas Clinics in 2009–2012. Gene
methylation was investigated with methylation-specific PCR. The study was approved by the Lithuanian Biomedical
Research Ethics Committee.
Results: The frequencies of methylation in cancerous tissues from the upper, middle, and lower thirds of the stomach
were 11.1, 23.1, and 45.4 %, respectively, for MLH1; 22.2, 30.8, and 57.6 %, respectively, for MGMT; and 44.4, 48.7, and
51.5 %, respectively, for DAPK-1. MLH1 and MGMT methylation was observed more often in the lower third of
the stomach than in the upper third (p < 0.05). In the middle third, DAPK-1 promoter methylation was related
to more-advanced disease in the lymph nodes (N2–3 compared with N0–1 [p = 0.02]) and advanced tumor
stage (stage III rather than stages I–II [p = 0.05]). MLH1 and MGMT methylation correlated inversely when the tumor
was located in the lower third of the stomach (coefficient, –0.48; p = 0.01). DAPK-1 and MLH1 methylation correlated
inversely in tumors in the middle-third of the stomach (coefficient, –0.41; p = 0.01).
Conclusion: Gene promoter methylation depends on the gastric tumor location.
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Background
Gastric cancer is a serious health problem. The con-
cealed clinical progress of the illness means that this
disease is typically diagnosed in its late stages, leading to
poor prognoses, despite the new treatment opportunities
that have emerged recently.
More than 90 % of stomach cancers are diagnosed
as adenocarcinoma [1]. Since 1965, gastric adenocar-
cinoma has been divided into two main types, diffuse
and intestinal (according to Lauren [2]). These two
histological types differ in their etiologies and progno-
ses. Intestinal and stomach adenocarcinomas are often
a consequence of chronic infection with Helicobacter
pylori, when the normal gastric mucosa transforms to
acute late chronic gastritis, intestinal metaplasia, and
dysplasia [3]. Diffuse adenocarcinoma is more aggressive
than the intestinal type, because its formation does not
depend on gastritis or metaplasia processes [4].
Recent scientific data show that the prognosis of
gastric adenocarcinoma depends not only on its histo-
logical type, but also on the tumor location in the
stomach. Proximal tumors (originating in the cardia),
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which usually form in response to gastroesophageal acid/
bile reflux [5], are now separated as a distinct and more
aggressive form of gastric adenocarcinoma, which differ
from distal stomach tumors.
Should distal stomach cancer be classified as unique?
Cohort studies have shown that the risk of the premalig-
nant condition, called ‘atrophic gastritis’, developing into
cancer differs according to the site of the lesion in the
stomach. The relative risk of gastric cancer occurring in
patients with corpus-predominant gastritis is higher than
in those with predominantly antral gastritis [6]. Does
this fact indicate different carcinogenic processes in the
stomach antrum and corpus? There are no data to either
exclude or confirm this.
Epigenetic modifications play a central role in gastric
carcinogenesis [7]. These processes, such as the methyla-
tion of CpG islands in gene promoter regions, cause
reversible structural changes in the DNA, which in turn
modify gene expression [8]. DNA methylation occurs
when a methyl group (–CH3) is transferred to the 5
th
position of cytosine [9].
A previous pilot study by our research group showed
that the frequency of methylation of the MLH1 pro-
moter differs in the corpus and antral stomach tissues
affected by pangastritis. We noticed that this epigenetic
process is significantly more frequent in the antral
gastritis tissues than in the corpus [10], whereas the
degree of atrophic gastritis is similar in both regions. It
is unclear whether this tendency is also true of cancer-
ous tissues.
Two groups of genes were selected for this methylation
analysis. The first group (MLH1 and MGMT) contains
two genes that encode proteins involved in repair of muta-
tions and other DNA lesions before further cell division,
and the second group contains a tumor-suppressing gene
(DAPK-1) encoding a protein that induces apoptosis in
the presence of a severe genomic defect.
The MLH1 (mutL homolog 1, colon cancer, nonpoly-
posis type 2 (E. coli)) gene occurs at the 3p21.3 locus.
The gene-encoded protein identifies DNA errors that
appear after replication. Hypermethylation of the MLH1
promoter, and not mutation-caused changes in the protein
function, is responsible for the microsatellite instability in
gastric cancer [11]. According to the literature, MLH1
methylation is responsible for the intestinal form of gastric
cancer and the early stage of the disease [12–16].
The function of MGMT (O6-methylguanine-DNA-
methyltransferase) is to remove the alkyl group from
the O6 position of guanine [17]. Disruption of the
MGMT function may cause the emergence of muta-
tions. Scientific publications indicate that the methylation
of the MGMT gene promoter is one of the pathogen-
etic pathways in gastric cancer. In particular, gene
methylation is attributed to the advanced stage of the
disease [18], and is also attributed to the poorer disease
prognosis [19].
The DAPK-1 (death-associated protein kinase 1) gene
is one of three DAPK family genes encoding calcium/
calmodulin-dependent serine–threonine protein kinases.
The function of the DAPK-1 protein is closely related to
various apoptosis pathways, and DAPK-1 hypermethyla-
tion has been shown to occur in solid and hematological
tumors.
Gastric cancer is not an exception. Gene promoter
methylation is also typical of adenocarcinomas in this
location. In an earlier study, our group found an inverse
association between DAPK-1 and MLH1 methylation
[20]. We test here the hypothesis that different gene
methylation profiles occur in cancerous tissues in the
stomach according to the site of the tumor (upper,
middle, or lower third).
Methods
The study was approved by the Lithuanian Regional
Biomedical Research Ethics Committee. All patients
signed an informed consent form. Patients treated at
the Lithuanian University of Health Sciences Hospital
(LUHSH) Kaunas Clinics in 2009–2012 participated
in the study. Stomach tissue samples were taken from
all subjects with morphologically confirmed stage I–III
adenocarcinoma. The study population consisted of 81
patients (34 men and 47 women) with a median age of 68
years (range 23–87 years; standard deviation [SD] 11.75).
The tumors of nine patients were in the upper third of the
stomach, those of 39 patients were in the middle third,
and those of 33 patients were in the lower third of the
stomach. The stomach tissue samples were collected from
the tumor sites during surgery. These materials were
immediately frozen in liquid nitrogen and stored at
−80 °C until analysis. During the study, the patients’
clinical data (age at diagnosis, sex) and morphological
data (tumor invasion according to the TNM classification,
histological type according to the Lauren classification,
and degree of differentiation according to the World
Health Organization classification) were obtained from
medical records.
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from 25–30 mg of frozen tissue using
the ZS Genomic DNA™ Tissue Mini Prep Kit (Zymo
Research, USA), according to the manufacturer’s instruc-
tions. The methylation status of the MLH1, MGMT, and
DAPK-1 promoters was determined by treating the DNA
with bisulfite, using the EZ DNA Methylation Gold Kit™
(Zymo Research), according to the manufacturer’s instruc-
tions. Human genomic DNA from peripheral blood
lymphocytes, treated with bisulfite, was used as the nega-
tive control. Human genomic DNA treated in vitro with
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SssI methyltransferase (New England Biolabs, UK) was
used as the positive control. The methylation status of the
promoters was detected with MSP.
The primers for the methylated and unmethylated
DNA sequences are listed in Table 1. PCR was performed
in a total reaction volume of 20 μL, containing 10 μL of
Maxima® Hot Start PCR Master Mix with Hot Start Taq
DNA Polymerase (Thermo Fisher Scientific, USA) and
10 μM of each primer (Metabion International AG,
Germany). MSP was performed for 38–40 cycles of
denaturation at 94 °C for 30 s, annealing for 1 min at
the temperature appropriate for the individual gene,
and extension at 72 °C for 1 min. The PCR products
were separated by 3.5 % agarose gel electrophoresis
(Fig. 1). When both methylated and unmethylated sig-
nals appeared on a gel, the gene was considered to be
methylated.
Mathematical–statistical data analysis
Statistical data analysis was performed with the SPSS
Statistics 19 software package (IBM SPSS Inc., USA).
Quantitative properties were described by the arithmetic
mean and standard deviation. Student’s t-test was used
to verify the hypothesis of equal means. The χ2 criterion
and Fisher’s exact test were used to check the statistical
hypothesis of independence of two variables. Correla-
tions between variables were evaluated by calculating
Spearman’s coefficient. p < 0.05 was deemed significant.
Results
The frequencies of promoter methylation in cancerous
tissues from the upper, middle, and lower thirds of the
stomach were 11.1, 23.1, and 45.4 %, respectively, for the
MLH1 gene; 22.2, 30.8, and 57.6 %, respectively, for the
MGMT gene; and 44.4, 48.7, and 51.5 %, respectively, for
the DAPK-1 gene. Methylation of the MLH1 and MGMT
genes was observed more often in the lower third of the
stomach than in the upper third (p < 0.05). The detailed
data are given in Table 2. A sex-based subgroup analysis
revealed that MLH1 methylation in the cancer tissues of
the lower-third stomach was typical of the female popu-
lation (p = 0.01), whereas MGMT methylation was only
statistically significant in the male group (p = 0.03). The
reasons for these findings are unclear, and require detailed
analysis and further studies. The promoter methylation of
the analyzed genes was not related to patient age.
The two main histological classification categories –
intestinal and diffuse types of tumors – reflect the differ-
entiation of the tumor and the tendency of the cancerous
cells to proliferate and spread. Therefore, we evaluated the
possible associations between the frequency distributions
of DAPK-1, MLH1, and MGMT methylation and the
Lauren morphological tumor classification. The results
are presented in Table 3. Because only a small number of
patients had histologically confirmed mixed-type adeno-
carcinoma according to the Lauren classification (n = 7),
this group was assigned to the more aggressive diffuse
form of the disease.
According to our data, methylation of the DAPK-1
promoter was more frequent in intestinal-type gastric
adenocarcinoma. However, this was merely a trend
because the results were not statistically significant
(p = 0.06). A subgroup analysis according to the tumor
location revealed that the frequency of DAPK-1 promoter
methylation was significantly related to the intestinal
cancerous tissue when the tumor was detected in the
upper third of the stomach (p = 0.02; Table 3). No associ-
ation was identified between the methylation of MLH1 or
MGMT and the tumor type according to the Lauren
classification.
We also analyzed the association between the methyla-
tion frequency of the same genes and tumor invasion
into the stomach wall (category T). The methylation of
genes MLH1 and MGMT was not associated with the T
category of the TNM classification of the cancerous
tissue in any part of the stomach. More frequent methy-
lation of DAPK-1 was observed in advanced tumors in
the middle third of the stomach, but this was not statis-
tically significant (p = 0.06), although this trend should
be explored in the future.
The correlation between gene promoter methylation
and lymph-node involvement was analyzed, but revealed
no significant association between the methylation of the
MLH1 and MGMT promoters and the tumor lymph-node
status. However, the apoptosis-related gene DAPK-1 was
more often methylated in the cancerous tissues in the N3
Table 1 Primers used for MSP
Primer name Forward sequence Reverse sequence Reference number
MLH1 methylated TATATCGTTCGTAGTATTC [GenBank:NG_0071092] TCCGACCCGAATAAACC [40]
MLH1 unmethylated TTTTGATGTAGATGTTTTATTAGGGT [GenBank:NG_0071092] TACCACCTCATCATAACTACC [40]
MGMT methylated TTTCGACGTTCGTAGGTTTTCGC [GenBank:NG_000010.11] GCACTCTTCCGAAAACGAAAC G [40]
MGMT unmethylated TTTGTGTTTTGATGTTTGTAGGTTTTTGT [GenBank:NG_000010.11] AACTCCACACTCTTCCAAAAACAAAACA [40]
DAPK-1 methylated GGATAGTCGGATCGAGTTAACGTC [GenBank:NG_029883.1] CCCTCCCAAACGCCG A [40]
DAPK-1 unmethylated GGAGGATAGTTGGATTGAGTTAATGTT [GenBank:NG_029883.1] CAAATCCCTCCCAAACACCAA [40]
bp base pairs
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category of the TNM classification (when tumor me-
tastasis is found in ≥ 7 regional lymph nodes) than in
those in the N0–2 category (p = 0.05). A subgroup
analysis showed that this association was only signifi-
cant in the cancerous tissues of the middle third of
the stomach (p = 0.01).
When the tumors were classified according to the
TNM system, we found no association between the
methylation of these genes and the tumor stage. How-
ever, a more precise analysis of the subgroups showed
that the methylation of the MLH1 promoter tended to
be more frequent in cancerous tissues in the middle
third of the stomach in stage I–II tumors than in stage
III tumors (p = 0.06). Epigenetic changes in the DAPK
gene were detected significantly more frequently in
gastric cancerous tissue from the middle third of the
stomach in stage III tumors than in stage I–II tumors
(p = 0.05).
The results of our study indicate an inverse correlation
between the methylation of the MLH1 and MGMT genes
in gastric cancer tissues when the tumor was located
in the lower third of the stomach (coefficient, –0.48;
p = 0.01). An inverse correlation between the methylation
of DAPK and MLH1 was also demonstrated in the cancer-
ous tissue in the middle third of the stomach (coefficient,
–0.41; p = 0.01).
Discussion
MLH1
According to the literature, the frequency of MLH1
methylation in cancerous gastric tissues ranges from 14
to 43 % [12–16]. These wide variations in the frequency
of MLH1 methylation can be attributed to the different
geographic regions considered in particular studies. The
anatomical distribution of stomach tumor sites is known
to differ in different geographic regions. In regions where
the incidence of H. pylori infection is high (Eastern
Europe, Eastern Asia), noncardial or distal gastric
cancer is diagnosed most often. However, in Western
and Northern Europe, where the number of H. pylori-
infected people is quite low, the number of proximal
gastric cancers is high. The scientific literature reports
that the methylation of the MLH1 promoter in stomach
cancer tissues is significantly related to the H. pylori
DAPK-1                                 
L    MC   UC   MC- UC- M     U     M     U     M     U      M     U     M      U     M     U      L 
MLH1
L    MC   UC   MC- UC- M     U     M     U     M     U      M     U     M      U     M     U     L 
MGMT
L    MC   UC   MC- UC- M     U     M     U     M     U      M     U     M      U     M     U     L 
L ladder , MC positive methylated control, UC positive unmethylated control, MC-
negative methylated control, UC- negative unmethylated control, M methylated allele,
U unmethylated allele.
Fig. 1 Representative samples of MSP analyses of DNA samples taken from stomach cancer tissues
Table 2 Distribution of MLH1, MGMT, and DAPK-1 methylation in cancerous gastric tissues according to stomach site
Stomach upper third cancerous tissue
(9 patients) M/U
Stomach middle-third cancerous tissue
(39 patients) M/U
Stomach lower-third cancerous tissue
(33 patients) M/U
p value
MLH1 1/8 9/30 15/18 0.05
MGMT 2/7 12/27 19/14 0.01
DAPK-1 4/5 19/20 17/16 0.93
M methylated allele, U unmethylated allele
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Table 3 Distribution of MLH1, MGMT, DAPK-1 methylation according to tumor site and pathological characteristics






























Intestinal type 0/3 6/16 7/10 1/2 5/17 8/11 3/0 12/10 10/7
Diffuse type 1/5 3/14 8/8 1/5 7/10 11/5 1/5 7/10 7/9
p value 0.45 0.48 0.61 0.57 0.22 0.21 0.02 0.41 0.39
T1 0/1 1/2 2/4 0/1 1/2 4/2 1/0 2/1 4/2
T2 0/2 2/2 2/3 0/2 1/3 3/2 1/1 0/4 3/2
T3 0/2 5/11 8/9 1/1 4/12 10/7 1/1 6/10 7/10
T4 1/3 1/15 3/2 1/3 6/10 2/3 1/3 11/5 3/2
p value 0.7 0.17 0.83 0.62 0.88 0.84 0.59 0.06 0.67
N0 0/4 5/9 6/4 2/2 4/10 5/5 3/1 4/10 6/4
N1 0/2 2/4 3/5 0/2 2/4 5/3 0/2 2/4 4/4
N2 0/2 1/6 3/2 0/2 1/6 3/2 1/1 2/5 1/4
N3 1/0 1/11 3/7 0/1 5/7 6/4 0/1 11/1 6/4
p value 0.29 0.33 0.48 0.36 0.66 0.95 0.27 0.01 0.46












virulence factor encoded by the vacs1 gene [21]. This
gene, which is typically detected in the bacterial genome,
provokes a more-intensive inflammatory response and is
related to an increased risk of gastric cancer in patients
with atrophic gastritis [22]. Chronic gastric mucosal in-
flammation, which is characterized by the mucosal infil-
tration of polymorphonuclear leukocytes, macrophages,
and T and B lymphocytes, leads to the release of reactive
oxygen species (ROS) from activated inflammatory cells.
ROS induce DNA damage and the lack of a proper
function of the mismatch repair system [23]. This is a
multistep process that depends on the intensity of in-
flammation. The methylation of the MLH1 promoter
occurs in a late stage of atrophic gastritis, intestinal
metaplasia [10, 24].
This consistent pattern is also supported by data from
a study of patients from Western and Northern Europe
[13]. Almost one third of the patients were diagnosed
with proximal (cardial) gastric cancer, and the frequency
of MLH1 methylation was 14.2 %. This epigenetic change
is also more frequently detected in distal gastric cancerous
tissue [13]. The results of our study show that the occur-
rence of MLH1 methylation in gastric cancer tissue in-
creases from the upper and middle third of the stomach
to the lower third, and was 11.1, 23.1, and 45.4 %, respect-
ively. As in the literature, we also showed that this epigen-
etic change occurs significantly more often in the lower
third of the stomach than in its proximal third, and this
effect is more pronounced in the female population. The
reason for sex related differences is unclear, further
investigations are needed.
Some data have indicated that the methylation of the
MLH1 promoter is detected significantly more frequently
in intestinal-type cancerous stomach tissues (according to
the Lauren classification) than in the diffuse type [15, 16].
Our results show that the distribution of this epigenetic
change is similar across tumor types according to Lauren
classification.
We found no significant association between the methy-
lation of MLH1 and the T and N criteria for cancerous
tissues in any part of the stomach. A separate analysis
according to the tumor site showed that the epigenetic
change (MLH1 methylation) tended to be more frequent
in cancerous tissue from the middle third of the stomach
when in stage I–II tumors than in stage III tumors
(p = 0.06). This result may not have been statistically
significant because the number of patients with early-
stage disease was relatively small.
We have found no published analysis of the relationship
between this epigenetic change and the T, N, and stage
criteria according to the tumor site in the stomach. How-
ever, published data indicate that, in general, the methyla-
tion of MLH1 in cancerous tissues is detected more often
when regional lymph nodes are not involved [14].
MGMT
The rate of methylation of the MGMT promoter in can-
cerous tissues increased from the upper to the lower third
of the stomach (22.2, 30.8, and 57.6 %, respectively), and
this effect is more pronounced in the male population.
The reason for sex related differences is unclear, further
investigations are needed. According to the literature,
MGMT methylation in cancerous stomach tissues ranges
from 7 to 61 % [13, 25–28]. This wide variation could be
explained by the fact that this epigenetic change is
detected more often in distal stomach cancer tissue than
at proximal sites [18, 29].
We found no significant associations between MGMT
promoter methylation and the T and N criteria or the
histological type of the tumor according to the Lauren
classification at any investigated stomach site. The loss
of the MGMT protein function is related to tumor
spread to the lymph nodes [14, 18] and advanced stages
of the disease [18, 30]. In our study, the number of pa-
tients with early-stage disease was comparatively small,
which could explain our findings.
DAPK-1
In this study, the frequency of DAPK-1 promoter methy-
lation did not correlate with tumor location. Published
data show that its frequency varies from 22 to 91 %
[28, 31–36]. According to our data, methylation of the
DAPK-1 promoter was more frequent in the intestinal
type of gastric adenocarcinoma. However, this was merely
a trend because the differences were not significant
(p = 0.06). A subgroup analysis according to the tumor
location showed that the frequency of DAPK promoter
methylation was significantly higher in intestinal cancer-
ous tissues in the upper third of the stomach. We found
no associations mentioned in literature between DAPK-1
promoter methylation and tumor classification according
to the Lauren. Our results should be interpreted critically
because of the few patients in this subgroup.
We noted a marginal trend in which DAPK-1 methyla-
tion was detected more frequently in the middle third
of the stomach in more advanced tumors, according
to the T criterion (p = 0.06). We also found that when
the apoptosis-related gene DAPK-1 was methylated in
cancerous tissues, the tumor was more likely to be N3 on
the TNM classification (tumor metastases found in ≥ 7
regional lymph nodes) than N0–2 (p = 0.05) and to be
an advanced tumor (stage III rather than stages I–II;
p = 0.05). A subgroup analysis showed that this associ-
ation occurs in cancerous tissues from the middle third of
the stomach (p-0.01), but is not significant at other
stomach sites. A study published in 2010 showed that the
methylation of the pro-apoptotic gene DAPK-1 in cancer-
ous stomach tissues is related to tumor spread to the
lymph nodes [37], but we did not find any information in
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the mentioned study linking these findings to different
sites of stomach cancer localizations.
Correlation between the methylation status of the
analyzed genes
The relationships between the promoter methylation of
the different genes in stomach cancer tissues were exam-
ined our study. Do these correlations depend on the
tumor site? We have found no information in the scien-
tific literature regarding the correlation of MGMT and
MLH1 promoter methylation in stomach adenocarcin-
oma tissues. The results of our study indicate that there
was an inverse correlation between the methylation of
MLH1 and MGMT in cancer tissues when the tumor
was located in the lower third of the stomach (coefficient,
–0.48; p = 0.01).
These results are not surprising because the methyla-
tion of both gene promoters is more often detected in
the lower-stomach cancer tissues [13, 29]. However, the
proteins encoded act in different stages of carcinogen-
esis. MLH1 promoter methylation is more often detected
in the early stages and in less aggressive gastric tumors
[12–16], whereas MGMT promoter methylation is more
typical of late-stage stomach adenocarcinomas and poor
prognoses [18, 19].
More information is available about the association be-
tween the promoter methylation of MLH1 and DAPK-1.
High microsatellite instability correlates inversely with
the methylation of the DAPK-1 promoter [12]. Our re-
search group identified an inverse, albeit weak, correlation
between the promoter methylation of DAPK-1 and MLH1,
regulating microsatellite function, in cancerous stomach
tissues [20].
We also found that this correlation occurs in the middle
third of the stomach. An inverse correlation between the
methylation of DAPK-1 and MLH1 was also identified in
cancer tissues sampled from the middle third of stomach
(coefficient, –0.41; p = 0.01).
The specific limitation of this study is that no informa-
tion on the mRNA expression of the analyzed genes was
provided. Our team plans to undertake this with quantita-
tive PCR in a future study. The current findings are
important not only because they extend our understand-
ing of gastric carcinogenesis, but also from the clinical
perspective. There is a growing body of evidence that
gene methylation in cancerous gastric tissues is asso-
ciated with differential sensitivity to chemotherapy.
Methylation of the MLH1 gene is related to resistance
to oxaliplatin-based chemotherapy [38], and patients
with DAPK-1 methylation show a worse response to
fluoropyrimidine-based chemotherapy [39].
We hope that our study will lead to better understand-
ing of the different pathways of molecular carcinogenesis
in different parts of the stomach.
Conclusion
Our study results show that an epigenetic process, the
methylation of gene promoters, in cancerous tissue
depends on the location of the gastric tumor.
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